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Portable Pumps and Controlled Drug Toxicity
Keep More Patients Ambulatory and at Home
The need for close monitoring of chronically ill patients
has traditionally led physicians
to hospitalize these patients.
But advances in therapy and
technology are allowing more
M. D. Anderson patients to
benefit from outpatient therapy either in the Ambulatory
'lieatment Center-the outPeter McLaughlin
patient chemotherapy area-or
even their own comfortable homes. It's less expensive,
more convenient, and, most important, just as effective as
inpatient treatment.
"Physicians at many institutions are conservative in evaluating patients for hospitalization, but I think that's
changing as a result of economic hard times, DRGs, and
advances in technology,'' said Peter McLaughlin, M. D.,
associate professor, Department of Hematology, and
member-at-large of the Patient Education Chemotherapy
Committee.
Primary obstacles to effective outpatient treatment are
toxicity and complex administration schedules of chemotherapeutic agents. The·hydration needed for therapy with
cisplatin, for example, once required patients to be hospitalized for close monitoring and hydration. Now the necessary supervision can be achieved during the patients' treatment in the Ambulatory 'lieatment Center. Twenty-fourhour-a-day continuous infusion therapy with doxorubicin,
for instance, can also be done by outpatients with the portable infusion pumps now available. Recent reports have
suggested that the cardiotoxicity of doxorubicin is reduced
if the drug is given as a continuous infusion over a prolonged period, McLaughlin said.

Complications Caused by Toxicity
Even though toxic effects generally can be reduced to
allow outpatient therapy, some patients still need hospital
monitoring. Patients who are debilitated by underlying diseases or by cancer-related problems may need inpatient
monitoring. "A patient with congestive heart failure who
is receiving cisplatin needs careful regulation of intravenous
fluids. Overhydration could easily exacerbate the heart failure. On the other hand, another patient on the same protocol might be treated as an outpatient. Underlying medical
problems affect our decision on whether or not to admit a
patient to the hospital," McLaughlin said.

Weyre always looking for
ways w keep patients out
of the hospital.

Similarly, diabetic lymphoma patients undergoing treatment with the ESHAP protocol (etoposide, methylprednisone [Solu-Medrol], cytarabine [high-dose Ara-CJ, and cisplatin) or other steroid-containing regimens may need
careful inpatient monitoring. "The steroids can aggravate
the patient's diabetes," McLaughlin explained, ''but nondiabetics can receive ESHAP as outpatients."
continued on page 7
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Chemoprevention of Colorectal Cancer
by Michael}. Wargovich, Ph.D.
Section ofGastrointestinal Oncology and Digestive Diseases
Department ofMedical Oncology

and synthetic forms of vitamin A. 11-ials of beta-carotene
and its analogue, 13-cis-retinoic acid, are in progress at several medical centers. In our department, t he first clinical
trial using beta-carotene or 13-cis-retinoic acid will begin
soon for patients with oral leukoplakia, a lesion that often
precedes oral cancer. Waun Ki H ong, M. D., chief of the
Section of Head and Neck Oncology, is the principal
investigator.
Vitamin A is found in precursor compounds, carotenoids, in green and yellow vegetables, and in dairy products; it is stored in the liver. The carotenoids are active
inhibitors of several carcinogen-induced cancers in animals,
but at high doses both the carotenoids and retinoids have
toxic side effects. The adverse nature of vitamin A compounds is being investigated, and new analogues that have
low toxicity yet retain their chemopreventive activity are
being made.
One phenomenon noted from the vitamin A studies represents a generalization of the chemopreventive agents'
activity: high doses seem to be needed to attempt to reverse
the neoplastic process. Because of the possibility of reaching
toxic thresholds, human cancer chemoprevention trials are
conservatively managed and the patients t ightly monitored
for adverse effects.
Other kinds of chemopreventive agents abound in foods.
Vitamins C and E, present in citrus fruits and many vegetables, have been shown in laboratory studies to block the
formation of nitrosamines, suspected to be etiologic agents
in several types of gastrointestinal cancer in humans. In a
current NCI-sponsored trial, physicians seek to determine
whether large doses of both vitamins prevent the recur-

Consider the average individual at risk for colon cancer.
What risk factors come to mind?
Certainly one recognizes age as a factor: cancer of the colon
and rectum has often been called a disease of the elderly.
The average age of the 150,000 Americans who will develop
colorectal cancer in 1988 will be 50 years or more. In light
of this association, persons over 40 are often advised to have
a digital exam as part of an annual physical examination
and, beginning at age 50, a periodic sigmoidoscopic exam.
But what other factors are associated with risk? Cancer of
the colon is also considered a genetic disease, genetic predisposition often manifested by such premalignant syndromes as ulcerative colitis, familial polyposis coli,
Gardner's syndrome, and Lynch family syndrome, each
with diagnostic features familiar to physicians.
But the risks related to familial or genetic factors account
for only 10% to 20% of colon cancer patients seen in the
clinic. Cancer of the colon is also considered an environmental disease, and research has focused predominantly on
aspects of the human diet as possible causes. Demographic
and epidemiologic investigations have pointed to profound
dietary differences among populations throughout the
world. Largely, these investigations implicated amounts
and types of macronutrients as risk factors in colon cancer.
Ingestion of high amounts of dietary fat was suggested as a
causal factor, for example, whereas the consumption of
fiber-rich fruits and vegetables seems to confer protection.
Recent laboratory studies also identified micronutrients,
substances included in the diet in small quantities, that
have the ability to retard, inhibit, or in some cases reverse
the neoplastic process. Active micronutrients that prevent
or inhibit cancer have been called chemopreventive agents.
In this sense, chemoprevention, which describes this new
discipline of cancer research, encompasses studies involving
prevention of cancer through use of naturally occurring
agents.

Chemopreventive Agents
Compounds of potential use in preventing human cancer
have been identified through in vitro, animal, and epidemiologic studies . This work, sponsored mainly by the
National Cancer Institute's Chemoprevention Branch, has
already yielded a number of agents that survived the rigorous journey from animal screening and efficacy studies to
incorporation into clinical trials with patients at high risk
for cancer.
Most of the current effort has concentrated on natural

Senior research assistant Cindy Woods with Michael Wargovich .
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rcnce ofrectal polyps in patients who have had a "cleansing" sigmoidoscopy. Compounds under experimental
investigation in animals include the minerals selenium and
calcium, protease inhibitors (found in legumes), thioethers
(i n onions and garlic), terpenes (in citrus fruits), indoles
and isothiocyanates (in cruciferous vegetables), phenolic
acids (in many fruits and vegetables), and several forms of
dietary fiber.
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characterized by an autosomally dominant, inherited disorder that causes the formation of many polyps in the colon;
familial polyposis patients, therefore, participate in several
chemoprevention trials currently under way.
More work needs to be done to identify the asymptomatic high-risk individuals in the general population. New
laboratory techniques may become available to gauge risk
long before the appearance of an indicator lesion. At our
institution, this approach might include initial screening in
the Special Risk Clinic of the Community Oncology Program headed by Rodger Winn, M.D. After a patient's
medical evaluation in the Gastrointestinal Oncology and
Digestive Diseases Clinic, biopsy samples would be tested
in research laboratories for biological markers of high risk.
Parameters to be measured would include in vitro measures
of cellular proliferation (thymidine kinetics and polyamine
levels), DNA ploidy, expression of selected oncogenes, and
expression of molecular markers for growth factors and differentiation. Researchers and clinicians could then judgebased on family history, health status, and biological
markers-whether the individual indeed has a high risk of
developing colon cancer. Then the patient could choose to
enter a chemoprevention protocol or be assigned to rigorous follow-up, or both.

Evaluation of Chemopreventive Agents
Based largely on epidemiologic and natural product
chemical studies, we are evaluating prospective cancer chemopreventive agents in a number of animal models. The
first step in the evaluation is to test the agent in in vivo
screening assays, which are designed to gain information
rapidly, in weeks rather than months, about an agent's
activity. The assays in this category include DNA-binding
and damage assays and inhibition of such cytogenetic endpoints as micronucleus formation. Our laboratory is under
NCI contract to perform these "first-pass" studies of chemoprevention agents.
Promising agents that pass the initial screening will be
scrutinized in extended studies with animals. The tests,
intended to determine the suppression of chemically
induced cancers, require chronic exposure of animals to the
potential cancer-inhibiting agent. Animal tumor models
selected for these studies are those with high relevance to
the most common human cancers, those of the colon,
breast, lung, skin, pancreas, and prostate. Dosage and efficacy will be formulated, side effects noted, and a preclinical
pharmacology assessment made. These data will permit the
design of phase I clinical intervention trials, and this poses
a larger question. Which groups of patients are candidates
for cancer chemoprevention trials? How to identify the
person at high risk for cancer is a significant challenge for
clinicians and researchers.

Promising New Agents
Work in our laboratory has focused on two promising
agents for the prevention of colon cancer. Diallyl sulfide, a
naturally occurring sulfur compound found in certain
members (garlic and onions) of the A Ilium family, was
shown in experimental trials substantially to protect mice
from developing colon cancer, despite their exposure to a
potent colonic carcinogen. We recently showed that the
same compound completely inhibits experimentally
induced esophageal cancer in rats; now we are trying to
identify the mechanism by which the sulfur compound
confers protection.
In investigations of calcium and its ability to control cellular proliferation induced by a fat-rich diet, we showed
that calcium added to the diet regulates the cells' stimulu:>sl
o--protiferare-; a11d i11 pdti-ents.1t-hi-gh-risk-fon:olon--cance
studied elsewhere, calcium was shown to modify mucosal
proliferation. The mechanism may be linked to cancer prevention. Our clinical efforts include a recently begun protocol to examine the effect of added calcium carbonate on.
mucosa! proliferation in patients who had polyps of the
colon removed. By comparing proliferative markers before
and after introduction of calcium, we hope to add to the
accumulating information that increased calcium intake
may help to prevent colon cancer.

Candidate for Chemoprevention:
The Person at High Risk
Chemoprevention trials must necessarily involve persons
at high risk for the common malignancies such as cancer of
the breast, lung, or colon, diseases with long latency
periods before they are diagnosed. These cancers share the
problem of difficult clinical management when the disease
has progressed. Cancer prevention trials using malignancy
as an endpoint are unfeasible because of such trials' duration and cost. The more common cancers, however, often
have associated premalignant indicator lesions-dysplasia of
the cervix, actinic keratoses of the skin, and adenomatous
polyps of the colon, for example-that could serve as endpoints. As mentioned, genetic predisposition often takes
the form of recognizable syndromes. Familial polyposis is

continued on page 6
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Clarifications of Tumor Cell Diversification
Bring New Ideas for Stopping the Process
Obstacle to Treatment

Isaiah J. Fidler

The emergence of metastases in organs distant from the primary tumor is the most devastating aspect of cancer, Fidler
said in an interview, and the biologic heterogeneity caused by
the constant evolution of tumor cells is the greatest obstacle
to successful treatment. This implies that effective treatment
must result in the eradication of all cancer cells, which so far
has not been possible.
Fidler and his group are now studying freshly isolated human
neoplasms to identify their normal and neoplastic cell populations and the genetic and epigenetic mechanisms of tumor
progression. In these studies in vitro and in investigations
with mice, the researchers hope to clarify both the diverse
characteristics of metastatic cells and their growth in different
organ environments.
One promising approach to eradicating tumor cells that
resist convential therapies is the systemic activation of macrophages, which are cells engaged, among other functions, in
recognizing and disposing of aged cells, cellular debris, and
foreign invaders.

Garth L. Nicolson

Two UT MDAH scientists who last fall were awarded
Outstanding Investigator Grants by the National Cancer
Institute discuss their work from somewhat different
views, but the central point is the same: Isaiah J. Fidler,
D.V.M., Ph.D., chairman of the Department of Cell
Biology, and Garth L. Nicolson, Ph.D., chairman of the
Department of Tumor Biology, test new ideas to learn how
cancer cells diversify and move to new sites in the body.
Both are concerned with the heterogeneity of these mechanisms and with translating the knowledge to treatment.
The National Cancer Institute awards are encouraging to
the scientists and their teams because the grants are a generous recognition oflong-standing productive cancer research
to
and because the sums-$3.35 million to Nicolson's research
group and $2. 45 million to Fidler's for the next seven yearsacute methods a disea/l ihat
relieve the scientists of some of the administrative burden
of frequently renewing grant support for their work.
took years to incubate . .:;c
Among Fidler's many recent publications is a review written with Charles M. Balch, M.D., head of the UT MDAH
Division of Surgery, "The Biology of Cancer Metastasis
and Implications for Therapy,'' in the March 1987 issue of
Current Prob !ems in Su,;gery.
In it the authors emphasize that the major goal of surgi__ caLand_clinicaLonrnlogis_t ~mains_th_e_p_r_e_\T__enti_o_n_o~r- - - - --------.-'-'W
_ e_h_o__.p,__e_t_o---;-l_e_a-r- ;n_- - -,'~g..,_e_n_e_ra_l_.ly,_,,__t_h--e_
-= r_o_le-- -=o_:_f_m
_ a_:c-=_: ro_:-__JpLh:-=-a: 3:g2-::e_s:_::_ __:in
:_=-=-_ _~
eradication of cancer metastasis," and in some 70 pages of
the pathogenesis of cancer metastasis and to understand how
fairly brusque, clear prose they explain what is known
activated macrophages discriminate between tumorigenic and
about the development and spread of metastatic cells.
normal cells. Specifically, we want to achieve maximal stimuPatterns of cancer growth and spread are not random,
lation of appropriate macrophages in patients to destroy
although many of the genetic and biochemical processes
treatment-resistant tumor cells, and some of these methods
are not yet understood. What is known now, however, is
are now being tested in the clinic,'' Fidler said.
that by the time a tumor is diagnosed, it may be biologically
Information gathered on cell heterogeneity and tumor spread,
heterogeneous and may already have spread to regional or
so far, he said, leads to questions that may be bothersome to
distant sites. This biological diversity has important
clinicians because "the human tendency to categorize things,
implications for research and for therapy.
to put things in boxes, has led to broad cancer categories that
may be inadequate for developing effective treatment."
The etiology of colon cancer, for example, is likely to be different in a patient who is 20 years old from one who is 70-the

The tendency is

4

tre;) with

January-March 1988

20-year-old person has not had time to develop diet-related
disease, Fidler said. As for melanoma, ''10 different patients
with the same type of melanoma of the skin may represent 10
different stages of disease, and each tumor may be heterogeneous within itself. "
By the time they are diagnosed, Fidler said, melanomas and
many other cancers contain diverse cell populations with different characteristics of growth rate, karyotype, cell-surface
properties, immunogenicity, marker enzymes, sensitivity to
cytotoxic drugs, response to radiation , ability to invade and
produce metastasis.

cells as possible. But this allows the survival of certain cells,
usually the ones that are most unstable and diversify rapidly.
This leads to wave after wave of cytotoxic therapy against
an ever more refractory and metastatic cell population. ' '
To interrupt this process-to cause tumor cells to stop
diversifying after they survive cytotoxic therapy-Nicolson
and Reuben Lotan, Ph.D., are studying the alternation of
cytotoxic and cytostatic treatment cycles, using as cytostatic agents biologic response modifiers like interferons,
differentiation factors, and vitamin analogues. These can
stop tumor cell division while the organism recovers (so far
the work has been done in mice) before a new hard-line
cytotoxic agent is used again. A patient might undergo this
kind oftwo-sided treatment for years, unlike therapy solely
with toxic drugs, which is limited by toxicity and the diversification of surviving tumor cells.

Take Advantage of D ifferences

-
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li-eatment protocols might be designed to take advantage
of the cellular and developmental differences of neoplastic
diseases. Certainly, a malignant tumor that has an incubation period of two to t hree weeks and is in an explosive
phase requires rapid treatment, Fidler said. But the " mirror image of this is that chronic forms of cancer may not be
amenable to acute treatments. "
Most cancers do not develop in days or weeks, in some
cases not even months, he said. " We suspect a prolonged
etiology of years. M elanoma, for example, may occur in
individuals who were exposed to UV light during their
early childhood. So when an infant runs on the beach
naked, the initiating events of melanoma may take place
then, but the disease may develop years later. The tendency
is to treat with acute methods a disease that took years to
incubate. We want to see t umors melt away, regress in
weeks. This may work in the case of some tumors, but for
others it may not be t he logical approach because the cells
follow a different biologic schedule. "
Data from his and Nicolson's laboratories, Fidler said,
show that metastatic growth in an organ environment is a
highly selective process that depends on both tumor cell
properties and organ characteristics. Scientists in Nicolson 's
group, for example, are isolating metastatic tumor cell
growth factors unique to certain organs, and in Fidler's laboratory researchers are looking for ways to short-circuit the
contribution of the host organ to the growth of metastases.
That knowledge will lead to better subdivision and better
dassification ofpatients=-'--'--bettenather-than~busier~dto better treatments, Fidler believes. "We can now image
some tumors with monoclonal antibodies. And we can
identify the presence of some cancers by circulating carcinoembryonic antigens. I believe that when new ideas prove
effective, they will be embraced. "

What looks like randomness
... may actually be built-in
diversificatwn.

Fetal Process Turned Back On
In the case of cellular proliferation, Nicolson said, " we
believe that what looks like randomness or heterogeneity
may actually be built-in diversification. It's not accidental
that fetal characteristics crop up in cancer development,
because we are learning that genetic programs that encode
these fetal characteristics are inadvertently turned on in
cancer. Many cancer markers we thought were specific for
cancer are actually developmental markers. Two of these are
carcinoembryonic antigen and alphafetoprotein, which are
expressed at high levels during embryonic diversification
and differentiation of certain tissues."
Cancer cells often go baclcto a more~'-'primitive~srare,
he explained, which means that genetic programs that control diversification and heterogeneity somehow became
active. "Ultimately, to really understand what's happening
we need to understand the genetic basis of these mechanisms. Primitive tumors that diversify rapidly and take on
more malignant characteristics seem to be similar in many
ways to cells at early embryonic stages, which are times
when they can literally metastasize to different parts of the
developing organism. In adult tissues, these characteristics
are believed to be inappropriate."

Cytotoxic/Cytostatic Therapy
"Some of the ideas we are trying to develop here,"
Nicolson said, "are not so much new therapies as better
use of existing ones. Right now cancer is being treated, for
the most part, with cytotoxic agents to kill as many cancer

continued on page 8
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Survey Yields Profile of Readers,
Helps to Refine Editorial Direction
A reader survey in the April-June 1987 issue of OncoLog
was designed to tell us who our readers are and how well
the newsletter's content fits their interests.
We found that we have a substantial, enthusiastic audience of physicians, most of them specialists in private practice, located mainly in urban and major metropolitan areas
of the Southwest but spread all over the globe. These readers
want information on new developments in cancer research
and treatment they can relate to the care of their patients.
Seventy percent of the respondents treat cancer patients,
and for about 40% cancer treatment is the major focus of
practice. Readers like OncoLog as it is, though they made
valuable suggestions for improving the editorial direction.

How Often, How Much, How Many?
Among 465 respondents who answered questions about
how frequently they read OncoLog, 87% read every issue,
12% read two or three issues a year, and 1 % read one a year.
As expected, most (63%) read specific articles; the other
37% read the newsletter cover to cover.
We thought that readers might pass their newsletters on
to associates, and 35% do. Those in group practice, hospital practice, and academic settings reported that they circulate their copies to about 473 others, including 273 physicians, 129 nurses, 71 students, and some interested spouses
and relatives practicing or studying medicine. Conservative
calculations cause us to conclude that we have about
23,000 pass-along readers, or about 1. 5 readers per copy.
When we asked what readers liked, 84% liked articles on
treatment, 64% liked articles on research, and 43% liked
news articles; 27% appreciated information on conferences .
Book reviews were generally disliked. Specific articles mentioned favorably included those on limited therapy for
Hodgkin's disease, adjuvant therapy for breast cancer, alternative treatment for prostate cancer, natural killer cells, liposomal drug delivery, cell survival and radiotherapy, hereditary colon cancer, and advances in chemotherapy. Some
readers cited volume and number, indicating that they
filed their copies and looked them up for this survey.
The major theme of suggestions for future articles was
practical clinical management of the more common
malignancies.
Thanks to all readers who answered the questions. We
like confirmation, and we understand criticism. ■

Among 465 respondents . ..
87% read every issue)
12% read two or three issues

a year) and 1% read
one a year.

We received 479 responses to the initial survey : 98% of the
respondents said that they read OncoLog, and 2% do not.
This kind of survey does not tell how many nonreaders we
have, so to learn how these numbers correspond to our total
continued from page 3
mailing list of more than 31,000 names, we sent a separate
survey to 100 people selected at random from the whole list.
~~~peruirnts to that s ~ ~ ~ n w b q g-, - - - - -Epitiemirn.egk~aHffitt-pr0ffilfiffiemist~, cellular~~
13. 5% do not, and another 13. 5% said that they do not
molecular biologists, and clinicians together are establishreceive it. (Since those names were all drawn from our mailing new research programs in chemoprevention. The first
ing list, we can only assume that the newsletter gets lost in
trials must enroll individuals at high risk for the most comthe mail or is filed or discarded before it is read.)
mon cancers such as colon cancer. Ultimately, physicians in
In the initial survey, the seven respondents who did not
the community will be in the vanguard of chemoprevenread the newsletter cited lack of interest or nonapplicability
tion trials in the general population. ■
to their fields as reasons for not reading it. Some respondents said that they are retired and no longer interested; in
Physicians who desire additional information may write Michael J.
contrast, others said they are retired and finally have time
Wargovich, Ph.D., Department of Medical Oncology, Box 68, The
to do some leisure reading in medicine; for them and othUniversity ofTexas M. D . Anderson Hospital and Tumor Institute at
ers, Oncowg serves as a quick review of the cancer field.
Houston, 1515 Holcombe Boulevard, Houston, Texas 77030.

Colorectal Cancer
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Outpatient Chemotherapy continued from page 1
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At times patients may require hospitalization before they
begin chemotherapy. ''When a tumor obstructs the biliary
tree, for example, we sometimes admit the patient to insert
a catheter for draining the biliary tree before beginning
therapy," McLaughlin said.
Hospitalization may also be necessary to treat patients for
threatening problems such as hypercalcemia or to observe
patients at risk of developing tumor lysis, which occurs in
some high-grade lymphomas . " Tumor lysis is a sudden
breakdown of the tumor, usually as a result of a rapid
response to chemotherapy. The breakdown products may
overload the kidneys and result in kidney failure or heartrhythm disturbances. These patients need careful monitoring and, occasionally, dialysis," McLaughlin said.
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Numerous Routes of Treating a Tumor
Chemotherapeutic agents may be administered by a
variety of routes. Some lend themselves to home treatment
more than others. Hormones for patients with breast cancer or chlorambucil for patients with low-grade lymphoma
may be taken orally. Subcutaneous or intramuscular agents
may be self-administered at home in the same way diabetics
give themselves insulin injections. Currently, the treatment
of hairy cell leukemia with interferon can be done in this
way, McLaughlin said.
The most common route of administration, however, is
intravenous, and if patients are to have intravenous chemotherapy at home, they need a portable pump and a central
venous catheter to connect to the pump. Single-drug protocols or even multidrug protocols with simple administration schedules can be adequately administered at home
with pumps currently available, but multidrug protocols
with complicated schedules are currently not practical for
administration in the home,
according to Edward Rubenstein, M.D., medical director
of the Ambulatory TI-eatment
Center.
"TI-aditionally, an obstacle to
outpatient chemotherapy was
simply that people had to have
several bags on a tall pole with
a large pump attached to it,"
. Edward Rubenstein
Rubenstein said. ''The logistics generally required inpatient care. Now we have smaller
pumps that can dispense four drugs at once. We are just
now examining how these more advanced devices can
enhance cancer treatment. In the near future, many of our
complicated multidrug protocols will be tested strictly on

Published quarterly by the Department of Scientific Publications,
Division of Academic Affairs, The University of Texas M.D.
Anderson Hospital and Tumor Institute at Houston, 1515 Holcombe
Boulevard , Houston, Texas 77030 . Made possible by a gift from
the late Mrs. Harry C. Wiess .

an outpatient basis." Advances in outpatient therapy will
depend in part on how effectively the new pumps administer several drugs several times a day.
"For instance, let's say a patient has a particular protocol
that calls for the infusion of a drug 24 hours a day over five
days and a second drug given once a day," Rubenstein said.
''What if this protocol also called for a third drug given
once a day, but at a different time than the second? That's
complicated. But if you have a programmable pump with
four channels, you simply load all the channels with the
drugs, program it the way the drugs should be given, and
hook it to the patient's catheter. The computer takes it
from there. That technology is coming."
Regardless of new developments in outpatient chemotherapy, Rubenstein said one thing is certain, "Whether it
be with new technology or improved therapy, we're always
looking for ways to keep patients out of the hospital.'' ■
Physicians who desire additional information may write Peter W.
McLaughlin, M.D., Department of Hematology, Box 47, and Edward B.
Rubenstein, M.D., Department of General Medicine, Box 78, The University of Texas M. D . Anderson Hospital and Tumor Institute at Houston, 1515 Holcombe Boulevard, Houston, Texas 77030.
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Tumor Cell Diversification continued from page 5
' Unless a patent i pr per! regi tered and Ii en ed to
company, the de ice will ta on the helf h aid.
icol on long-term goal i t under tand, hat g n rate the malignant phcnot pe
hat g e a, r g n tically, and how thi can be re ogni zed arl , and ntr lied
before it goe too far. F r thi we ha e t kn v , hat enc
to look at. That i wh our immcdiat g I arc ti d t ur
long-term one : finding the malignant tum r ph n t 'P
which is a more focu ed ta k th an findin th an er ph notype or the tumor phcnot 'P . nder rt in nditi n
when the malignant tumor phenot p be m
re lit
the tumor is capable of in ading pr adin t and univing at distant sites. Once e under tand h , the pr perties are controlled and regulated
m b abl t pre, nt
tumor cells from progre sing to more malion nt ph n types . Perhaps , e cane, en learn to make them revert t
less malignant states. ■

Malignancy and Gene Expression
icolson s basic tudies of gene expre ion and malignancy show that ome gene transcripts believed to be
in olved in the cell differentiation proce s are alwa present
but are expressed at higher or lower le, els when the cells
change from an es entiall benign to a malignant phenotype. Such change in gene expre sion eem to be quantitative not qualitative. Knowing this may help u
understand how to pre ent the proce s from occurring,'
icolson said.
His immediate goal is to de elop cancer marker that v ill
spot the tage of a tumor cell's malignant progre ion and
be specific for the high! malignant phenoq pe. ' This will
enable us to follow up breast cancer patient , for example ,
who have gone through their initial therapies and surgical
intervention, with blood tests every few months to check
for the presence or absence of markers for recurrent malignant disease," he said.
Nicolson and his associates are working on a half-dozen
patents, with more on the way for new procedures the
designed to test blood samples for these tumor markers.
The reason for patents, he explained , is not to make mone)
but to stimulate the methods ' commercial applic;ation.

Physicians who desire additional in fo rmat ion may write I aiah J. Fidler,
D . . M., Ph .D . Department of Cell Biology Box l 3, and Garth L.
icol on, Ph .D . Department ofTumor Biology Box 108, The ni\'ersity o fTexas M . D. Ander on H o pita! and Tum or I n titute at Hou ton,
1515 H olcombe Boulevard , H ou ton , Texa
030 .
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